Skip Navigation


JAC Advance Access first published online on March 30, 2007
This version published online on April 3, 2007
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkm077
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
59/5/941    most recent
dkm077v3
dkm077v2
dkm077v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Smith, P. J.
Right arrow Articles by Adler-Moore, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, P. J.
Right arrow Articles by Adler-Moore, J. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B

Peter J. Smith1, Jon A. Olson1, David Constable1, Julie Schwartz2, Richard T. Proffitt3 and Jill P. Adler-Moore1,*

1 Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA 2 Pathology Associates Division, Charles River Laboratories, Inc., Davis, CA 95616, USA 3 RichPro Associates, 2095 Lavender Hill Ct., Lincoln, CA 95648, USA

Received 19 December 2006; returned 9 January 2007; revised 10 February 2007; accepted 12 February 2007

* Corresponding author. Tel: +1-909-869-4047; Fax: +1-909-869-4078; E-mail: jpadler{at}csupomona.edu

Objectives: We hypothesized that effective prophylactic treatment of fungal infections would require adequate drug penetration and retention at potential infection sites. Using a mouse model, we examined liposomal amphotericin B (L-AmB) biodistribution, cell localization and retention in kidneys, lungs, liver and spleen to evaluate effective dosing regimens for prophylaxis of Candida glabrata and Candida albicans infections.

Methods: Following treatment of mice with cumulative doses of L-AmB (60–225 mg/kg), a bioassay was done to determine tissue drug concentrations 12 h to 6 weeks post-treatment. Immunohistochemical staining with anti-amphotericin B antibodies was used for cellular drug localization. Mice were treated prophylactically with 15–90 mg/kg L-AmB and challenged intravenously 1–7 days later with C. glabrata or they were given a total of 60 mg/kg as daily or intermittent dosing followed by intravenous challenge with C. albicans 3 or 6 weeks later.

Results: On the basis of µg/g tissue, the relative amount of drug was in the order spleen > liver > kidneys > lungs. Amphotericin B levels were maintained above the MIC for many fungi for 1 week in lungs and for as long as 6 weeks in kidneys and spleen. Drug localized in kidney tubular epithelial cells and in macrophages of liver and spleen. In prophylactic models, fungal burden was reduced by several 1000-fold or was undetectable within target tissues (kidneys, spleen).

Conclusions: These observations underscore the importance of including drug tissue levels to obtain a better understanding of L-AmB efficacy. The sustained concentrations of bioactive AmB in many tissues provide a further rationale for investigating L-AmB prophylactic regimens.

Key Words: lipid formulations , bioavailability , candidiasis , antifungal agents


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
S. Weiler, G. Falkensammer, A. Hammerer-Lercher, M. Anliker, H. Vogelsinger, M. Joannidis, S. Dunzendorfer, M. Stein, and R. Bellmann
Pulmonary Epithelial Lining Fluid Concentrations after Use of Systemic Amphotericin B Lipid Formulations
Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4934 - 4937.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
M. Ellis, R. Bernsen, H. Ali-Zadeh, J. Kristensen, U. Hedstrom, L. Poughias, M. Bresnik, A. Al-Essa, and D. A. Stevens
A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever
J. Med. Microbiol., November 1, 2009; 58(11): 1474 - 1485.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. O. Gubbins, J. R. Amsden, S. A. McConnell, and E. J. Anaissie
Pharmacokinetics and Buccal Mucosal Concentrations of a 15 Milligram per Kilogram of Body Weight Total Dose of Liposomal Amphotericin B Administered as a Single Dose (15 mg/kg), Weekly Dose (7.5 mg/kg), or Daily Dose (1 mg/kg) in Peripheral Stem Cell Transplant Patients
Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3664 - 3674.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. Gershkovich, E. K. Wasan, M. Lin, O. Sivak, C. G. Leon, J. G. Clement, and K. M. Wasan
Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation
J. Antimicrob. Chemother., July 1, 2009; 64(1): 101 - 108.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.